Drug Makers Stocks Under Scanner -- Teva Pharma, Endo, Ionis Pharma, and Amarin
NEW YORK, March 27, 2017 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com dedicates attention to four equities in the Drug Manufacturers space, which are: Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International PLC (NASDAQ: ENDP), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Amarin Corp. PLC (NASDAQ: AMRN). These companies are part of the Healthcare sector, which was narrowly mixed just before the closing bell on Friday, March 24th, 2017, with the NYSE Health Care Index falling about 0.2%, while shares of health care companies in the S&P 500 still were up 0.1% as a group. You can access our complimentary research reports on these stocks now at:
Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd's stock finished last Friday's session 0.09% higher at $32.76 with a total trading volume of 4.13 million shares. Shares of the Company, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, are trading below their 50-day moving average by 3.09%. The stock has a Relative Strength Index (RSI) of 41.85.
On February 28th, 2017, research firm Argus downgraded the Company's stock rating from 'Buy' to 'Hold'.
On March 17th, 2017, Teva Pharma announced the launch of the Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) 1 mg/20 mcg in the US. The Authorized Generic of Minastrin® 24 Fe is an estrogen/progestin combined oral contraceptive indicated for use by women to prevent pregnancy. Visit us today and download your complete report on TEVA for free at:
On Friday, shares in Dublin, Ireland headquartered Endo International PLC ended the session 0.20% lower at $9.97. The stock recorded a trading volume of 5.90 million shares. The Company's shares are trading 17.51% below their 50-day moving average. Moreover, shares of Endo International, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 33.45.
On March 14th, 2017, Endo International announced that the US FDA's Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted 18 to eight, with one abstention, that the benefits of reformulated OPANA® ER no longer outweigh its risks. Following the vote, a number of Committee members expressed their preference that OPANA® ER remain on the market with additional regulatory restrictions to mitigate the risks. The complimentary research report on ENDP can be accessed at:
Carlsbad, California headquartered Ionis Pharmaceuticals Inc.'s shares gained 2.77%, closing the session at $38.98 with a total trading volume of 1.50 million shares. The stock is trading 5.02% above its 200-day moving average. Shares of the Company, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 37.47.
On February 28th, 2017, Ionis Pharma reported that it outperformed its financial guidance by ending 2016 with pro-forma operating income of $25.8 million, and $665.2 million in cash, cash equivalents and short-term investments. The Company also reported a GAAP loss from operations of $46.3 million.
On March 10th, 2017, research firm Goldman downgraded the Company's stock rating from 'Neutral' to 'Sell'. Register for free on Stock-Callers.com and download the PDF research report on IONS at:
Last Friday at the close, shares in Dublin, Ireland-based Amarin Corp. PLC recorded a trading volume of 947,800 shares. The stock ended the session 1.59% higher at $3.19. The Company's shares have advanced 4.59% over the previous three months and 3.57% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.21% and 7.59%, respectively. Furthermore, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 49.07.
On March 16th, 2017, Amarin announced the onset of approximately 80% of the target aggregate number of primary cardiovascular events within the REDUCE-IT study. This milestone has triggered preparation for a pre-specified interim efficacy and safety analysis by the study's independent Data Monitoring Committee. The Company currently expects the independent interim analysis to be conducted before the end of the third calendar quarter of this year. Get free access to your research report on AMRN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA